Sai Life Sciences Limited disclosed that its promoters and promoter group members did not encumber any shares directly or indirectly during the financial year ended March 31, 2026. This declaration was made by Krishnam Raju Kanumuri, a promoter of the company, in a filing submitted to the National Stock Exchange of India Limited and BSE Limited on April 07, 2026. The disclosure confirms that no new encumbrances were created beyond those previously reported during the financial year.

The filing was made pursuant to Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. This regulation requires promoters to disclose any encumbrance of shares to ensure transparency in shareholding patterns. The document specified that the declaration covers the promoter and promoter group, including Persons Acting in Concert (PAC).

The submission included an exhaustive list of individuals and entities falling under the promoter and promoter group categories. The list comprises 48 entries, ranging from individual promoters to various partnership firms, private limited companies, and family trusts. Krishnam Raju Kanumuri signed the declaration on behalf of the promoters, promoter group, and PAC.

List of Promoters and Promoter Group

The following table details the entities classified as promoters and promoter group members as per the disclosure:

Sai Life Sciences Limited has scheduled meetings with analysts and investors in Mumbai for June 3 and June 4, 2026, as part of its engagement with the financial community. The company will participate in the Morgan Stanley India Investment Forum 2026 and the Citi India Conference 2026 during this period. These interactions provide a platform for the company to present its operational strategy and performance to potential investors.

The meetings are being conducted in accordance with Regulations 30 read with Schedule III of the SEBI (Listing Obligations and Disclosures Requirements) Regulations 2015. Runa Karan, Company Secretary & Compliance Officer, confirmed the schedule in a filing submitted to the stock exchanges on May 27, 2026.

The company clarified that it does not intend to discuss any unpublished price sensitive information during the meetings. Additionally, no new presentation is scheduled to be released for these events. The schedule remains subject to changes based on exigencies on the part of the analysts, investors, or the company.